{"component": "contracts", "props": {"contracts": [{"intro": "", "id": "5slXMK6bCR5", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000079297719000137/ex102.htm", "category_name": "Supply Agreement", "company_name": "Amag Pharmaceuticals, Inc.", "created": "November 1st, 2019", "published": true, "pretty": null, "uri": "/contracts/5slXMK6bCR5", "title": "SUPPLY AGREEMENT", "group_id": "5slXMK6bCR5", "group_samples": [{"label": "Supply Agreement (Palatin Technologies Inc)", "uri": "/contracts/eOx7AvYrCte", "published": true}, {"label": "Supply Agreement (Amag Pharmaceuticals, Inc.)", "uri": "/contracts/5slXMK6bCR5", "published": true}], "group_size": 2, "tags": [{"name": "Supply Agreement", "type": "category", "uri": "/contracts/tagged/supply-agreement"}, {"name": "Amag Pharmaceuticals, Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This STOCKHOLDERS AGREEMENT, dated as of July 19, 2011 (this \"Agreement\"), is entered into by and between AMAG Pharmaceuticals, Inc. (the \"Company\") and Warburg Pincus Private Equity VIII, L.P. (the \"Stockholder\").", "id": "6AUmE5U4e8Z", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000104746911006536/a2204880zex-10_3.htm", "category_name": "Stockholders Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "July 22nd, 2011", "published": true, "pretty": null, "uri": "/contracts/6AUmE5U4e8Z", "title": "STOCKHOLDERS AGREEMENT July 19, 2011", "group_id": "6AUmE5U4e8Z", "group_samples": [{"label": "Stockholders Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/6AUmE5U4e8Z", "published": true}, {"label": "Stockholders Agreement (Warburg Pincus Private Equity Viii L P)", "uri": "/contracts/8H4VbcfZ43V", "published": true}], "group_size": 2, "tags": [{"name": "Stockholders Agreement", "type": "category", "uri": "/contracts/tagged/stockholders-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This Commercial Supply Agreement (this \"Agreement\"), effective as of the 4th day of June, 2018 (the \u201cEffective Date\u201d), is entered into by and between:", "id": "6L514g6me7u", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000079297718000073/ex108.htm", "category_name": "Commercial Supply Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "December 21st, 2018", "published": true, "pretty": null, "uri": "/contracts/6L514g6me7u", "title": "COMMERCIAL SUPPLY AGREEMENT", "group_id": "6L514g6me7u", "group_samples": [{"label": "Commercial Supply Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/6L514g6me7u", "published": true}, {"label": "Commercial Supply Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/d3M8nfUxYaA", "published": true}], "group_size": 2, "tags": [{"name": "Commercial Supply Agreement", "type": "category", "uri": "/contracts/tagged/commercial-supply-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "cxxzun81kcA", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000090873707000245/ex1-1.htm", "category_name": "Underwriting Agreement", "company_name": "Advanced Magnetics Inc", "created": "May 24th, 2007", "published": true, "pretty": null, "uri": "/contracts/cxxzun81kcA", "title": "2,500,000 SHARES ADVANCED MAGNETICS, INC. COMMON STOCK, $0.01 PAR VALUE PER SHARE UNDERWRITING AGREEMENT", "group_id": "6QGUiM2VEbg", "group_samples": [{"label": "Underwriting Agreement (Advanced Magnetics Inc)", "uri": "/contracts/cxxzun81kcA", "published": true}, {"label": "Underwriting Agreement (Advanced Magnetics Inc)", "uri": "/contracts/6QGUiM2VEbg", "published": true}], "group_size": 2, "tags": [{"name": "Underwriting Agreement", "type": "category", "uri": "/contracts/tagged/underwriting-agreement"}, {"name": "Advanced Magnetics Inc", "type": "company", "uri": "/company/792977/advanced-magnetics-inc"}, {"name": "In vitro & in vivo diagnostic substances", "type": "industry", "uri": "/contracts/tagged/in-vitro-in-vivo-diagnostic-substances"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "reported in patients receiving Feraheme/Rienso. Serious adverse reactions of clinically significant hypotension have been reported in the post-marketing experience of Feraheme/Rienso.", "id": "6UbnNKLyHSb", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000104746915000871/a2223053zex-10_19.htm", "category_name": "Termination Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "February 18th, 2015", "published": true, "pretty": null, "uri": "/contracts/6UbnNKLyHSb", "title": "INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT...", "group_id": "6UbnNKLyHSb", "group_samples": [{"label": "Termination Agreement", "uri": "/contracts/hqNJezT02Rm", "published": true}, {"label": "Termination Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/6UbnNKLyHSb", "published": true}], "group_size": 2, "tags": [{"name": "Termination Agreement", "type": "category", "uri": "/contracts/tagged/termination-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Employment Agreement (the \u201cAgreement\u201d) is entered into as of February 7, 2006 by and between Advanced Magnetics, Inc., a Delaware corporation with offices at 61 Mooney Street, Cambridge, MA 02138 (\u201cAMI\u201d) and Joseph L. Farmer, of 484 East Seventh Street, Boston, MA 02127 (\u201cyou\u201d).", "id": "6tRFfrBvs50", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000090873706000105/ex10-7.htm", "category_name": "Employment Agreement", "company_name": "Advanced Magnetics Inc", "created": "February 13th, 2006", "published": true, "pretty": null, "uri": "/contracts/6tRFfrBvs50", "title": "EMPLOYMENT AGREEMENT", "group_id": "6tRFfrBvs50", "group_samples": [{"label": "Employment Agreement (Advanced Magnetics Inc)", "uri": "/contracts/6tRFfrBvs50", "published": true}, {"label": "Employment Agreement (Advanced Magnetics Inc)", "uri": "/contracts/aKTuoj3FaHY", "published": true}], "group_size": 2, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Advanced Magnetics Inc", "type": "company", "uri": "/company/792977/advanced-magnetics-inc"}, {"name": "In vitro & in vivo diagnostic substances", "type": "industry", "uri": "/contracts/tagged/in-vitro-in-vivo-diagnostic-substances"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH \u201c[\u2026***\u2026]\u201d. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED UNDER THE SECURITIES ACT OF 1934, AS AMENDED.", "id": "kTo8344FWrq", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000110465917006291/a17-3667_1ex10d1.htm", "category_name": "License Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "February 3rd, 2017", "published": true, "pretty": null, "uri": "/contracts/kTo8344FWrq", "title": "LICENSE AGREEMENT by and between AMAG PHARMACEUTICALS, INC. and PALATIN TECHNOLOGIES, INC. January 8, 2017", "group_id": "7DnImJLe0TX", "group_samples": [{"label": "License Agreement (Palatin Technologies Inc)", "uri": "/contracts/7DnImJLe0TX", "published": true}, {"label": "License Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/kTo8344FWrq", "published": true}], "group_size": 2, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ [FMV on Grant Date] Grant Date: Expiration Date: [up to 10 years]", "id": "d27mcIs9zm", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000079297720000027/ex10102019.htm", "category_name": "Incentive Stock Option Agreement", "company_name": "Amag Pharmaceuticals, Inc.", "created": "March 6th, 2020", "published": true, "pretty": null, "uri": "/contracts/d27mcIs9zm", "title": "AMAG PHARMACEUTICALS, INC. INCENTIVE STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES", "group_id": "7R6jVW0WIrE", "group_samples": [{"label": "Incentive Stock Option Agreement (Amag Pharmaceuticals, Inc.)", "uri": "/contracts/d27mcIs9zm", "published": true}, {"label": "Incentive Stock Option Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/7R6jVW0WIrE", "published": true}], "group_size": 2, "tags": [{"name": "Incentive Stock Option Agreement", "type": "category", "uri": "/contracts/tagged/incentive-stock-option-agreement"}, {"name": "Amag Pharmaceuticals, Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Contract Manufacturing Agreement is made by and between (1) Fresenius Kabi Austria GmbH, having its registered office at Hafnerstrasse 36, A-8055 Graz, Austria (\u201cFRESENIUS\u201d) and (2) AMAG Pharmaceuticals, Inc., a Delaware corporation having an office at 1100 Winter Street, Waltham, MA 02451, U.S.A. (\u201cCOMPANY\u201d), effective as of September 1, 2018 (the \u201cEffective Date\u201d).", "id": "7h558OiED90", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000079297719000036/ex10432018.htm", "category_name": "Contract Manufacturing Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "March 1st, 2019", "published": true, "pretty": null, "uri": "/contracts/7h558OiED90", "title": "CONTRACT MANUFACTURING AGREEMENT", "group_id": "7h558OiED90", "group_samples": [{"label": "Contract Manufacturing Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/7h558OiED90", "published": true}, {"label": "Contract Manufacturing Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/8QRAXmqLTwK", "published": true}], "group_size": 2, "tags": [{"name": "Contract Manufacturing Agreement", "type": "category", "uri": "/contracts/tagged/contract-manufacturing-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Employment Agreement (the \u201cAgreement\u201d) is entered into as of [Date] by and between AMAG Pharmaceuticals, Inc., a Delaware corporation with offices at 1100 Winter Street, Waltham, MA 02451 (together with its subsidiaries and affiliates, the \u201cCompany\u201d), and [Executive Name] of [Address] (\u201cyou\u201d or \u201cEmployee\u201d).", "id": "fvSvNcBv4bo", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000079297720000027/ex10202019.htm", "category_name": "Employment Agreement", "company_name": "Amag Pharmaceuticals, Inc.", "created": "March 6th, 2020", "published": true, "pretty": null, "uri": "/contracts/fvSvNcBv4bo", "title": "EMPLOYMENT AGREEMENT", "group_id": "7iMLcnHQb9P", "group_samples": [{"label": "Employment Agreement (Amag Pharmaceuticals, Inc.)", "uri": "/contracts/fvSvNcBv4bo", "published": true}, {"label": "Employment Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/7iMLcnHQb9P", "published": true}], "group_size": 2, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Amag Pharmaceuticals, Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "AMAG Pharmaceuticals, Inc., a Delaware corporation (the \u201cCompany\u201d), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the \u201cUnderwriters\u201d), for whom you are acting as representative (the \u201cRepresentative\u201d), $175,000,000 principal amount of its 2.50% Convertible Senior Notes due 2019 (the \u201cUnderwritten Securities\u201d) and, at the option of the Underwriters, up to an additional $25,000,000 principal amount of its 2.50% Convertible Senior Notes due 2019 (the \u201cOption Securities\u201d) if and to the extent that the Underwriters shall have determined to exercise the option to purchase such 2.50% Convertible Senior Notes due 2019 granted to the Underwriters in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the \u201cSecurities\u201d. The Securities will be convertible into cash, shares of common stock of the Company, par value $0.01 per share (the \u201cCommon Stock\u201d), or a combination of cash and shares of Common Stock at the Compan", "id": "bI8u4t5L8FL", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000110465914010090/a14-5247_9ex1d1.htm", "category_name": "Underwriting Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "February 14th, 2014", "published": true, "pretty": null, "uri": "/contracts/bI8u4t5L8FL", "title": "AMAG PHARMACEUTICALS, INC. Underwriting Agreement", "group_id": "88mBua5of8f", "group_samples": [{"label": "Underwriting Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/bI8u4t5L8FL", "published": true}, {"label": "Underwriting Agreement (Trinity Industries Inc)", "uri": "/contracts/88mBua5of8f", "published": true}], "group_size": 2, "tags": [{"name": "Underwriting Agreement", "type": "category", "uri": "/contracts/tagged/underwriting-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Termination Agreement (the \u201cTermination Agreement\u201d) contains representations, warranties and covenants that were made only for purposes of the Termination Agreement and as of specific dates; were solely for the benefit of the parties to the Termination Agreement; may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the Termination Agreement instead of establishing these matters as facts; and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Stockholders of AMAG and other investors and stakeholders are not third-party beneficiaries under the Termination Agreement and should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition of AMAG or any of its subsidiaries or affiliates. Mor", "id": "8kI6V7EWNH0", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000079297720000070/amagexhibit101-72720r.htm", "category_name": "Termination Agreement", "company_name": "Amag Pharmaceuticals, Inc.", "created": "July 27th, 2020", "published": true, "pretty": null, "uri": "/contracts/8kI6V7EWNH0", "title": "Certain confidential information contained in this document, marked by [***], has been omitted because AMAG Pharmaceuticals, Inc. (\u201cAMAG\u201d) has determined the information (i) is not material and (ii) would likely cause competitive harm to AMAG or its...", "group_id": "8kI6V7EWNH0", "group_samples": [{"label": "Termination Agreement (Amag Pharmaceuticals, Inc.)", "uri": "/contracts/8kI6V7EWNH0", "published": true}, {"label": "Termination Agreement (Palatin Technologies Inc)", "uri": "/contracts/9BRY9lksdSC", "published": true}], "group_size": 2, "tags": [{"name": "Termination Agreement", "type": "category", "uri": "/contracts/tagged/termination-agreement"}, {"name": "Amag Pharmaceuticals, Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (\"Agreement\") is made and entered into as of July 19, 2011, by and among AMAG PHARMACEUTICALS, INC., a Delaware corporation (\"Parent\"); ALAMO ACQUISITION SUB, INC., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"); and ALLOS THERAPEUTICS, INC., a Delaware corporation (the \"Company\"). Certain capitalized terms used in this Agreement are defined in Exhibit A.", "id": "9O4UcUGSTlm", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000104746911006537/a2204880zex-2_1.htm", "category_name": "Merger Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "July 22nd, 2011", "published": true, "pretty": null, "uri": "/contracts/9O4UcUGSTlm", "title": "AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: AMAG PHARMACEUTICALS, INC., a Delaware corporation; ALAMO ACQUISITION SUB, INC., a Delaware corporation; and ALLOS THERAPEUTICS, INC., a Delaware corporation", "group_id": "9O4UcUGSTlm", "group_samples": [{"label": "Merger Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/9O4UcUGSTlm", "published": true}, {"label": "Merger Agreement (Allos Therapeutics Inc)", "uri": "/contracts/j3UBHFR4GMb", "published": true}], "group_size": 2, "tags": [{"name": "Merger Agreement", "type": "category", "uri": "/contracts/tagged/merger-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This License Agreement (the \u201cAgreement\u201d), is made and entered into on June 6, 2013 (the \u201cEffective Date\u201d) by and between (i) AMAG Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business located at 100 Hayden Ave., Lexington, MA 02421 (\u201cAMAG\u201d) and (ii) Access Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business located at 2600 Stemmons Freeway, Suite 176, Dallas TX 75207 (\u201cAccess\u201d) (AMAG and Access are each a \u201cParty,\u201d and collectively the \u201cParties\u201d).", "id": "eZZPYDCgDri", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000110465913061018/a13-13684_1ex10d1.htm", "category_name": "License Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "August 7th, 2013", "published": true, "pretty": null, "uri": "/contracts/eZZPYDCgDri", "title": "LICENSE AGREEMENT", "group_id": "9lvX3sMP1wA", "group_samples": [{"label": "License Agreement (Access Pharmaceuticals Inc)", "uri": "/contracts/9lvX3sMP1wA", "published": true}, {"label": "License Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/eZZPYDCgDri", "published": true}], "group_size": 2, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "WHEREAS, Customer is engaged in the development and research of certain products and requires assistance in the development and manufacture of product;", "id": "m6Oed4XRwg", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000079297719000137/ex103.htm", "category_name": "Manufacturing Services Agreement", "company_name": "Amag Pharmaceuticals, Inc.", "created": "November 1st, 2019", "published": true, "pretty": null, "uri": "/contracts/m6Oed4XRwg", "title": "Manufacturing Services Agreement", "group_id": "acn7igG47ZK", "group_samples": [{"label": "Manufacturing Services Agreement (Palatin Technologies Inc)", "uri": "/contracts/acn7igG47ZK", "published": true}, {"label": "Manufacturing Services Agreement (Amag Pharmaceuticals, Inc.)", "uri": "/contracts/m6Oed4XRwg", "published": true}], "group_size": 2, "tags": [{"name": "Manufacturing Services Agreement", "type": "category", "uri": "/contracts/tagged/manufacturing-services-agreement"}, {"name": "Amag Pharmaceuticals, Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "Pursuant to the AMAG Pharmaceuticals, Inc. 2019 Equity Incentive Plan (the \u201cPlan\u201d), AMAG Pharmaceuticals, Inc. (the \u201cCompany\u201d) hereby grants an award of the number of Restricted Stock Units listed above (an \u201cAward\u201d) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.01 per share (the \u201cStock\u201d) of the Company.", "id": "cmFTcrooshR", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000079297720000027/ex10122019.htm", "category_name": "Restricted Stock Unit Award Agreement", "company_name": "Amag Pharmaceuticals, Inc.", "created": "March 6th, 2020", "published": true, "pretty": null, "uri": "/contracts/cmFTcrooshR", "title": "AMAG PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES", "group_id": "cmFTcrooshR", "group_samples": [{"label": "Restricted Stock Unit Award Agreement (Amag Pharmaceuticals, Inc.)", "uri": "/contracts/cmFTcrooshR", "published": true}, {"label": "Restricted Stock Unit Award Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/jZ8J4jsJ2hl", "published": true}], "group_size": 2, "tags": [{"name": "Restricted Stock Unit Award Agreement", "type": "category", "uri": "/contracts/tagged/restricted-stock-unit-award-agreement"}, {"name": "Amag Pharmaceuticals, Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Indemnification Agreement (the \u201cAgreement\u201d) dated as of , 200 , by and between AMAG Pharmaceuticals, Inc., a Delaware Corporation (the \u201cCompany\u201d); and , a director and/or officer of the Company (the \u201cIndemnitee\u201d):", "id": "fcRbADJEC4H", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000104746910001547/a2196774zex-10_2.htm", "category_name": "Indemnification Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "February 26th, 2010", "published": true, "pretty": null, "uri": "/contracts/fcRbADJEC4H", "title": "INDEMNIFICATION AGREEMENT", "group_id": "dTM1ducgTpN", "group_samples": [{"label": "Indemnification Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/fcRbADJEC4H", "published": true}, {"label": "Indemnification Agreement (Advanced Magnetics Inc)", "uri": "/contracts/dTM1ducgTpN", "published": true}], "group_size": 2, "tags": [{"name": "Indemnification Agreement", "type": "category", "uri": "/contracts/tagged/indemnification-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "In vitro & in vivo diagnostic substances", "type": "industry", "uri": "/contracts/tagged/in-vitro-in-vivo-diagnostic-substances"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "Risk Factors \u2014 We may not be successful in implementing Makena\u2019s lifecycle management program, which could have a negative impact on our business", "id": "eis5i7F6wkh", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000110465915055245/a15-16416_3ex1d1.htm", "category_name": "Underwriting Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "July 31st, 2015", "published": true, "pretty": null, "uri": "/contracts/eis5i7F6wkh", "title": "3,150,000 Shares AMAG Pharmaceuticals, Inc. UNDERWRITING AGREEMENT", "group_id": "eis5i7F6wkh", "group_samples": [{"label": "Underwriting Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/eis5i7F6wkh", "published": true}, {"label": "Underwriting Agreement (Parallel Petroleum Corp)", "uri": "/contracts/eOcnv8gjUTT", "published": true}], "group_size": 2, "tags": [{"name": "Underwriting Agreement", "type": "category", "uri": "/contracts/tagged/underwriting-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "AMAG Pharmaceuticals, Inc., a Delaware corporation (the \u201cCompany\u201d) hereby enters into this Restricted Stock Unit Agreement, dated as of the date set forth below, with the Recipient named herein (the \u201cAgreement\u201d) and grants to the Recipient the Restricted Stock Units (\u201cRSUs\u201d) specified herein as an inducement grant pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. This RSU grant satisfies the requirements of Section 3(c) of the Employment Agreement (as defined below).", "id": "hIifWwqr0pp", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000110465913061010/a13-17991_1ex4d2.htm", "category_name": "Restricted Stock Unit Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "August 7th, 2013", "published": true, "pretty": null, "uri": "/contracts/hIifWwqr0pp", "title": "AMAG PHARMACEUTICALS, INC. Restricted Stock Unit Agreement (Non-Plan Inducement Grant)", "group_id": "hIifWwqr0pp", "group_samples": [{"label": "Restricted Stock Unit Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/hIifWwqr0pp", "published": true}, {"label": "Restricted Stock Unit Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/jREqpF8vLXC", "published": true}], "group_size": 2, "tags": [{"name": "Restricted Stock Unit Agreement", "type": "category", "uri": "/contracts/tagged/restricted-stock-unit-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This Agreement and Plan of Merger (this \u201cAgreement\u201d) is made and entered into on October 1, 2020, by and among: Covis Group S.\u00e0 r.l., a Luxembourg company (\u201cParent\u201d); Covis Mergerco Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (\u201cMerger Sub\u201d); AMAG Pharmaceuticals, Inc., a Delaware corporation (the \u201cCompany\u201d) and, solely with respect to Sections 5.1, 5.2, 5.3, 5.4, 5.6, 6.14 and 6.15, Covis Finco S.\u00e0 r.l., a Luxembourg company and the direct parent of Parent (\u201cDebt Financing Borrower\u201d) .", "id": "eWKPueGKNrs", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000110465920111126/tm2032216d1_ex2-1.htm", "category_name": "Merger Agreement", "company_name": "Amag Pharmaceuticals, Inc.", "created": "October 1st, 2020", "published": true, "pretty": null, "uri": "/contracts/eWKPueGKNrs", "title": "AGREEMENT AND PLAN OF MERGER by and among Covis Group S.\u00e0 r.l., Covis Mergerco Inc., AMAG Pharmaceuticals, Inc.", "group_id": "i8e1t2x0H7I", "group_samples": [{"label": "Merger Agreement (Indus Realty Trust, Inc.)", "uri": "/contracts/i8e1t2x0H7I", "published": true}, {"label": "Merger Agreement (Amag Pharmaceuticals, Inc.)", "uri": "/contracts/eWKPueGKNrs", "published": true}], "group_size": 2, "tags": [{"name": "Merger Agreement", "type": "category", "uri": "/contracts/tagged/merger-agreement"}, {"name": "Amag Pharmaceuticals, Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "THIS AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (the \"Amendment\") is made and entered into as of August 8, 2011, by and among AMAG PHARMACEUTICALS, INC., a Delaware corporation (\"Parent\"); ALAMO ACQUISITION SUB, INC., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"); and ALLOS THERAPEUTICS, INC., a Delaware corporation (the \"Company\"); and this Amendment amends that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of July 19, 2011, by and among Parent, Merger Sub, and the Company. Capitalized terms used in this Amendment and not defined herein shall have the meanings given to such terms in the Merger Agreement.", "id": "kEvq85644a", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000104746911007108/a2205185zex-2_1.htm", "category_name": "Agreement and Plan of Merger and Reorganization", "company_name": "Amag Pharmaceuticals Inc.", "created": "August 9th, 2011", "published": true, "pretty": null, "uri": "/contracts/kEvq85644a", "title": "AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION", "group_id": "kEvq85644a", "group_samples": [{"label": "Agreement and Plan of Merger and Reorganization (Allos Therapeutics Inc)", "uri": "/contracts/kfllH9FsBLH", "published": true}, {"label": "Agreement and Plan of Merger and Reorganization (Amag Pharmaceuticals Inc.)", "uri": "/contracts/kEvq85644a", "published": true}], "group_size": 2, "tags": [{"name": "Agreement and Plan of Merger and Reorganization", "type": "category", "uri": "/contracts/tagged/agreement-and-plan-of-merger-and-reorganization"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This Registration Rights Agreement (this \"Agreement\") is made and entered into as of July 2, 2003, by and among Advanced Magnetics, Inc., a Delaware corporation (the \"Company\"), and the investors signatory hereto (each a \"Purchaser\" and collectively, the \"Purchasers\").", "id": "lAVs0KfCmLa", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000104746903025740/a2114999zex-4_3.htm", "category_name": "Registration Rights Agreement", "company_name": "Advanced Magnetics Inc", "created": "July 31st, 2003", "published": true, "pretty": null, "uri": "/contracts/lAVs0KfCmLa", "title": "REGISTRATION RIGHTS AGREEMENT", "group_id": "lAVs0KfCmLa", "group_samples": [{"label": "Registration Rights Agreement (Athena Gold Corp)", "uri": "/contracts/arelnEhlmvK", "published": true}, {"label": "Registration Rights Agreement (Advanced Magnetics Inc)", "uri": "/contracts/lAVs0KfCmLa", "published": true}], "group_size": 2, "tags": [{"name": "Registration Rights Agreement", "type": "category", "uri": "/contracts/tagged/registration-rights-agreement"}, {"name": "Advanced Magnetics Inc", "type": "company", "uri": "/company/792977/advanced-magnetics-inc"}, {"name": "In vitro & in vivo diagnostic substances", "type": "industry", "uri": "/contracts/tagged/in-vitro-in-vivo-diagnostic-substances"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This AGREEMENT is made and entered into by and between Advanced Magnetics, Inc., having its principal place of business at 61 Mooney St., Cambridge, MA 02138, and FoxKiser Development Partners LLC, having its principal place of business at 750 17th St., N.W., Suite 1100, Washington, DC 20006.", "id": "1KRl85Zqn2H", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000110465907037032/a07-13356_1ex10d2.htm", "category_name": "Affiliate Agreement", "company_name": "Advanced Magnetics Inc", "created": "May 8th, 2007", "published": true, "pretty": null, "uri": "/contracts/1KRl85Zqn2H", "title": "AGREEMENT", "group_id": "1KRl85Zqn2H", "group_samples": [{"label": "Affiliate Agreement (Advanced Magnetics Inc)", "uri": "/contracts/1KRl85Zqn2H", "published": true}], "group_size": 1, "tags": [{"name": "Affiliate Agreement", "type": "category", "uri": "/contracts/tagged/affiliate-agreement"}, {"name": "Advanced Magnetics Inc", "type": "company", "uri": "/company/792977/advanced-magnetics-inc"}, {"name": "In vitro & in vivo diagnostic substances", "type": "industry", "uri": "/contracts/tagged/in-vitro-in-vivo-diagnostic-substances"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "THIS ASSET PURCHASE AGREEMENT (this \u201cAgreement\u201d), dated as of May 21, 2020, is made by and between Millicent Pharma Limited, a company organized under the laws of Ireland (the \u201cPurchaser\u201d), and AMAG Pharmaceuticals, Inc., a Delaware corporation (the \u201cSeller\u201d). Capitalized terms used and not otherwise defined herein have the meanings set forth in Article XI. In this Agreement, the Seller and the Purchaser are individually referred to as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "1Niv3XTslBS", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000079297720000045/amagexhibit101-52120.htm", "category_name": "Asset Purchase Agreement", "company_name": "Amag Pharmaceuticals, Inc.", "created": "May 22nd, 2020", "published": true, "pretty": null, "uri": "/contracts/1Niv3XTslBS", "title": "ASSET PURCHASE AGREEMENT by and between AMAG PHARMACEUTICALS, INC. and MILLICENT PHARMA LIMITED May 21, 2020", "group_id": "1Niv3XTslBS", "group_samples": [{"label": "Asset Purchase Agreement (Amag Pharmaceuticals, Inc.)", "uri": "/contracts/1Niv3XTslBS", "published": true}], "group_size": 1, "tags": [{"name": "Asset Purchase Agreement", "type": "category", "uri": "/contracts/tagged/asset-purchase-agreement"}, {"name": "Amag Pharmaceuticals, Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This Amendment dated as of February 11, 2014 (this \u201cAmendment\u201d) to the Rights Agreement, dated as of September 4, 2009 (the \u201cRights Agreement\u201d), is entered into between AMAG PHARMACEUTICALS, INC., a Delaware corporation (the \u201cCompany\u201d), and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, as Rights Agent (the \u201cRights Agent\u201d). Capitalized terms used herein and not defined shall have the meanings specified in the Rights Agreement.", "id": "1TruSkJ6xDj", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000110465914010649/a14-5247_8ex4d4.htm", "category_name": "Rights Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "February 14th, 2014", "published": true, "pretty": null, "uri": "/contracts/1TruSkJ6xDj", "title": "AMENDMENT TO RIGHTS AGREEMENT", "group_id": "1TruSkJ6xDj", "group_samples": [{"label": "Rights Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/1TruSkJ6xDj", "published": true}], "group_size": 1, "tags": [{"name": "Rights Agreement", "type": "category", "uri": "/contracts/tagged/rights-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "In consideration for your long-term contributions to Advanced Magnetics, Inc. (the \u201cCompany\u201d) and in connection with the termination of your employment, this letter agreement outlines and confirms the terms and conditions of severance being offered to you as a result of your separation from employment with the Company.", "id": "1buCabBhn8Y", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000090873707000161/ex10-1.htm", "category_name": "Severance Agreement", "company_name": "Advanced Magnetics Inc", "created": "April 6th, 2007", "published": true, "pretty": null, "uri": "/contracts/1buCabBhn8Y", "title": "April 2, 2007", "group_id": "1buCabBhn8Y", "group_samples": [{"label": "Severance Agreement (Advanced Magnetics Inc)", "uri": "/contracts/1buCabBhn8Y", "published": true}], "group_size": 1, "tags": [{"name": "Severance Agreement", "type": "category", "uri": "/contracts/tagged/severance-agreement"}, {"name": "Advanced Magnetics Inc", "type": "company", "uri": "/company/792977/advanced-magnetics-inc"}, {"name": "In vitro & in vivo diagnostic substances", "type": "industry", "uri": "/contracts/tagged/in-vitro-in-vivo-diagnostic-substances"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "THIS FOURTH AMENDMENT TO LEASE dated as of this 1st day of January, 2018 is by and between BP BAY COLONY LLC, a Delaware limited liability company (\u201cLandlord\u201d), and AMAG PHARMACEUTICALS, INC., a Delaware corporation (\u201cTenant\u201d).", "id": "1jnBokAd7AP", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000079297718000023/ex101q12018.htm", "category_name": "Lease", "company_name": "Amag Pharmaceuticals Inc.", "created": "May 4th, 2018", "published": true, "pretty": null, "uri": "/contracts/1jnBokAd7AP", "title": "FOURTH AMENDMENT TO LEASE", "group_id": "1jnBokAd7AP", "group_samples": [{"label": "Lease (Amag Pharmaceuticals Inc.)", "uri": "/contracts/1jnBokAd7AP", "published": true}], "group_size": 1, "tags": [{"name": "Lease", "type": "category", "uri": "/contracts/tagged/lease"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Amendment to Amended and Restated Employment Agreement (the \u201cAmendment\u201d) is entered into as of November 29, 2017 (the \u201cEffective Date\u201d) by and between AMAG Pharmaceuticals, Inc., a Delaware corporation with offices at 1100 Winter Street, Waltham, MA 02451 (together with its subsidiaries and affiliates, the \u201cCompany\u201d), and William K. Heiden of [Address] (\u201cyou\u201d).", "id": "29ALwTuoDML", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000079297717000045/ex101.htm", "category_name": "Employment Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "November 30th, 2017", "published": true, "pretty": null, "uri": "/contracts/29ALwTuoDML", "title": "AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT", "group_id": "29ALwTuoDML", "group_samples": [{"label": "Employment Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/29ALwTuoDML", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This AMENDMENT NO. 2 (this \u201cAmendment\u201d), dated this 19th day of June, 2015 to the Pharmaceutical Manufacturing and Supply Agreement dated January 8, 2010, as amended (collectively, the \u201cAgreement\u201d), is made by and between AMAG Pharmaceuticals, Inc. (\u201cAMAG\u201d) and Patheon Manufacturing Services LLC (as assignee from DPI Newco LLC as assignee from DSM Pharmaceuticals, Inc.) (hereinafter \u201cPMSLLC\u201d).", "id": "2iFBPHbYl6B", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000155837015002383/amag-20150930ex10164a54a.htm", "category_name": "Pharmaceutical Manufacturing and Supply Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "November 6th, 2015", "published": true, "pretty": null, "uri": "/contracts/2iFBPHbYl6B", "title": "AMENDMENT NO. 2 TO PHARMACEUTICAL MANUFACTURING AND SUPPLY AGREEMENT", "group_id": "2iFBPHbYl6B", "group_samples": [{"label": "Pharmaceutical Manufacturing and Supply Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/2iFBPHbYl6B", "published": true}], "group_size": 1, "tags": [{"name": "Pharmaceutical Manufacturing and Supply Agreement", "type": "category", "uri": "/contracts/tagged/pharmaceutical-manufacturing-and-supply-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "The definitions and provisions contained in the 2002 ISDA Equity Derivatives Definitions (the \u201cEquity Definitions\u201d), as published by the International Swaps and Derivatives Association, Inc. (\u201cISDA\u201d) are incorporated into this Confirmation. In the event of any inconsistency between the Equity Definitions and this Confirmation, this Confirmation shall govern. Certain defined terms used herein are based on terms that are defined in the Prospectus dated November 6, 2013, as supplemented by the Prospectus Supplement dated February 11, 2014 (as so supplemented, the \u201cProspectus\u201d) relating to the Convertible Senior Notes due 2019 (as originally issued by Counterparty, the \u201cConvertible Notes\u201d and each USD 1,000 principal amount of Convertible Notes, a \u201cConvertible Note\u201d) issued by Counterparty in an aggregate initial principal amount of USD 175,000,000 (as increased by up to an aggregate principal amount of USD 25,000,000 if and to the extent that the Underwriters (as defined herein) exercises", "id": "2nAvWOqhVCF", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000110465914010649/a14-5247_8ex10d7.htm", "category_name": "Call Option Transaction", "company_name": "Amag Pharmaceuticals Inc.", "created": "February 14th, 2014", "published": true, "pretty": null, "uri": "/contracts/2nAvWOqhVCF", "title": "JPMorgan Chase Bank, National Association London Branch Canary Wharf London E14 5JP England", "group_id": "2nAvWOqhVCF", "group_samples": [{"label": "Call Option Transaction (Amag Pharmaceuticals Inc.)", "uri": "/contracts/2nAvWOqhVCF", "published": true}], "group_size": 1, "tags": [{"name": "Call Option Transaction", "type": "category", "uri": "/contracts/tagged/call-option-transaction"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "2raRh08CJ4T", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000079297719000137/ex104.htm", "category_name": "Termination of Distribution and Supply Agreement", "company_name": "Amag Pharmaceuticals, Inc.", "created": "November 1st, 2019", "published": true, "pretty": null, "uri": "/contracts/2raRh08CJ4T", "title": "Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark...", "group_id": "2raRh08CJ4T", "group_samples": [{"label": "Termination of Distribution and Supply Agreement (Amag Pharmaceuticals, Inc.)", "uri": "/contracts/2raRh08CJ4T", "published": true}], "group_size": 1, "tags": [{"name": "Termination of Distribution and Supply Agreement", "type": "category", "uri": "/contracts/tagged/termination-of-distribution-and-supply-agreement"}, {"name": "Amag Pharmaceuticals, Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Fourth Amendment to the Commercial Outsourcing Services Agreement (this \u201cAmendment\u201d) is between AMAG Pharmaceuticals, Inc. (the \u201cCompany\u201d) and Integrated Commercialization Solutions, Inc. (\u201cICS\u201d). This Amendment is effective as of August 1, 2013 (the \u201cAmendment Effective Date\u201d).", "id": "2uGvYcKM2Bh", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000110465913081687/a13-19582_1ex10d1.htm", "category_name": "Commercial Outsourcing Services Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "November 6th, 2013", "published": true, "pretty": null, "uri": "/contracts/2uGvYcKM2Bh", "title": "FOURTH AMENDMENT TO COMMERCIAL OUTSOURCING SERVICES AGREEMENT", "group_id": "2uGvYcKM2Bh", "group_samples": [{"label": "Commercial Outsourcing Services Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/2uGvYcKM2Bh", "published": true}], "group_size": 1, "tags": [{"name": "Commercial Outsourcing Services Agreement", "type": "category", "uri": "/contracts/tagged/commercial-outsourcing-services-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Amendment No. 2 (\u201cAmendment\u201d), effective as of March 31, 2015 (the \u201cEffective Date\u201d), entered into by and between (i) AMAG Pharmaceuticals, Inc. (\u201cAMAG\u201d or the \u201cCompany\u201d) and (ii) Sigma-Aldrich, Inc. (\u201cSAFC\u201d), amends that certain Commercial Supply Agreement between AMAG and SAFC dated August 29, 2012 (the \u201cCommercial Supply Agreement\u201d), as amended October 3, 2013 (\u201cAmendment No. 1\u201d), and collectively with the Commercial Supply Agreement, the \u201cAgreement\u201d). Capitalized terms used but not defined in this Amendment will have the meanings given them in the Agreement.", "id": "2vUD2NAaqh9", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000110465915053179/a15-11888_1ex10d2.htm", "category_name": "Commercial Supply Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "July 27th, 2015", "published": true, "pretty": null, "uri": "/contracts/2vUD2NAaqh9", "title": "AMENDMENT NO. 2", "group_id": "2vUD2NAaqh9", "group_samples": [{"label": "Commercial Supply Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/2vUD2NAaqh9", "published": true}], "group_size": 1, "tags": [{"name": "Commercial Supply Agreement", "type": "category", "uri": "/contracts/tagged/commercial-supply-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "Pursuant to the AMAG Pharmaceuticals, Inc. Third Amended and Restated 2007 Equity Incentive Plan as amended through the date hereof (the \u201cPlan\u201d), AMAG Pharmaceuticals, Inc. (the \u201cCompany\u201d) hereby grants an award of the number of Restricted Stock Units listed above (an \u201cAward\u201d) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.01 per share (the \u201cStock\u201d) of the Company.", "id": "33MaTlgPBA5", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000155837016003420/amag-20151231ex1013aecd8.htm", "category_name": "Restricted Stock Unit Award Agreement", "company_name": "Amag Pharmaceuticals Inc.", "created": "February 24th, 2016", "published": true, "pretty": null, "uri": "/contracts/33MaTlgPBA5", "title": "RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS", "group_id": "33MaTlgPBA5", "group_samples": [{"label": "Restricted Stock Unit Award Agreement (Amag Pharmaceuticals Inc.)", "uri": "/contracts/33MaTlgPBA5", "published": true}], "group_size": 1, "tags": [{"name": "Restricted Stock Unit Award Agreement", "type": "category", "uri": "/contracts/tagged/restricted-stock-unit-award-agreement"}, {"name": "Amag Pharmaceuticals Inc.", "type": "company", "uri": "/company/792977/amag-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "3JERHMdbRdV", "source_url": "https://www.sec.gov/Archives/edgar/data/792977/000091205700054096/a2033252zex-10_19.txt", "category_name": "License and Marketing Agreement", "company_name": "Advanced Magnetics Inc", "created": "December 19th, 2000", "published": true, "pretty": null, "uri": "/contracts/3JERHMdbRdV", "title": "EXHIBIT 10.19 LICENSE AND MARKETING AGREEMENT BY AND BETWEEN CYTOGEN CORPORATION", "group_id": "3JERHMdbRdV", "group_samples": [{"label": "License and Marketing Agreement (Advanced Magnetics Inc)", "uri": "/contracts/3JERHMdbRdV", "published": true}], "group_size": 1, "tags": [{"name": "License and Marketing Agreement", "type": "category", "uri": "/contracts/tagged/license-and-marketing-agreement"}, {"name": "Advanced Magnetics Inc", "type": "company", "uri": "/company/792977/advanced-magnetics-inc"}, {"name": "In vitro & in vivo diagnostic substances", "type": "industry", "uri": "/contracts/tagged/in-vitro-in-vivo-diagnostic-substances"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}], "next_curs": "CjEKEAoKZ3JvdXBfc2l6ZRICCAEKGQoIZ3JvdXBfaWQSDRoLM0pFUkhNZGJSZFYYACAB", "cursor": "CjEKEAoKZ3JvdXBfc2l6ZRICCAIKGQoIZ3JvdXBfaWQSDRoLNEJISTQxM2hTVVcYACAB"}}